Idursulfase Beta (Hunterase) Therapeutic Experience in a Patient with Mucopolysaccharidosis Type II

Background. Mucopolysaccharidosis type II (MPS II, Hunter syndrome) is an X-linked recessive disease caused by lysosomal enzyme iduronate-2-sulfatase deficiency resulting in progressive glycosaminoglycans (GAG) accumulation in tissues (dermatan sulfate and heparan sulfate). GAG accumulation in cells leads to the development of progressive pathological disorders, malfunction of various organs and systems, early disability, and decrease in life expectancy. Enzyme replacement therapy (ERT) reduces the rate of life-threatening conditions development in patient. ERT would be more effective if it is prescribed early, especially at preclinical stage. This is the time when there are no severe irreversible changes in the cell, thus, pathogenetic therapy will decrease GAG accumulation in lysosomes, slow down the pathological process, and improve patient's condition. Clinical case description. Male patient diagnosed with MPS II was administrated with ERT idursulfase beta at the age of 6 months. It led to milder disease course compared to proband uncle who had similar mutation in the IDS gene, severe disease phenotype, and later initiation of ERT (at the age of 2.5 years). Conclusion. Early ERT initiation in patients with MPS II significantly slows down development of severe and life-threatening complications, increases the duration and improves the quality of life.

1. Scarpa M. Mucopolysaccharidosis type II. In: GeneReviews®. Adam MP, Ardinger HH, Pagon RA, et al., eds. University of Washington, Seattle; SeattleWA: 1993.

2. Wraith JE, Scarpa M, Beck M, et al. Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. Eur J Pediatr. 2008;167(3):267–277. doi: https://doi.org/10.1007/s00431-007-0635-4

3. da Silva EMK, Strufldi MWL, Andriolo RB, Silva LA. Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter Syndrome). Cochrane Database Syst Rev. 2016;2(2):CD008185. doi: https://doi.org/10.1002/14651858.CD008185.pub4

4. D’Avanzo F, Rigon L, Zanetti A, Tomanin R. Mucopolysaccharidosis type II: one hundred years of research, diagnosis, and treatment. Int J Mol Sci. 2020;21(4):1258. doi: https://doi.org/10.3390/ijms21041258

5. Stapleton M, Arunkumar N, Kubaski F, et al. Clinical presentation and diagnosis of mucopolysaccharidoses. Mol Genet Metab. 2018;125(1-2):4–17. doi: https://doi.org/10.1016/j.ymgme.2018.01.003

6. Demydchuk M, Hill CH, Zhou A, et al. Insights into Hunter syndrome from the structure of iduronate-2-sulfatase. Nat Commun. 2017;8:15786. doi: https://doi.org/10.1038/ncomms15786

7. Hunter C. A Rare Disease in Two Brothers. Proc R Soc Med. 1917;10(Sect Study Dis Child):104–116. doi: https://doi.org/10.1177/003591571701001833

8. Khan SA, Peracha H, Ballhausen D, et al. Epidemiology of mucopolysaccharidoses. Mol Genet Metab. 2017;121(3):227–240. doi: https://doi.org/10.1016/j.ymgme.2017.05.016

9. Stapleton M, Kubaski F, Mason RW, et al. Presentation and treatments for Mucopolysaccharidosis Type II (MPS II; Hunter Syndrome). Expert Opin Orphan Drugs. 2017;5(4):295-307. doi: https://doi.org/10.1080/21678707.2017.1296761

10. Shapiro EG, Jones SA, Escolar ML. Developmental and behavioral aspects of mucopolysaccharidoses with brain manifestations — Neurological signs and symptoms. Mol Genet Metab. 2017;122S: 1–7. doi: https://doi.org/10.1016/j.ymgme.2017.08.009

11. Tomanin R, Zanetti A, D’Avanzo F, et al. Clinical efficacy of Enzyme Replacement Therapy in paediatric Hunter patients, an independent study of 3.5 years. Orphanet J Rare Dis. 2014;9:129. doi: https://doi.org/10.1186/s13023-014-0129-1

12. Rigante D, Segni G. Cardiac structural involvement in mucopolysaccharidoses. Cardiology. 2002;98(1-2):18–20. doi: https://doi.org/10.1159/000064674

13. Kim C, Seo J, Chung Y, et al. Comparative study of idursulfase beta and idursulfase in vitro and in vivo. J Hum Genet. 2017;62(2): 167–174. doi: https://doi.org/10.1038/jhg.2016.133

14. Chung YK, Sohn YB, Sohn JM, et al. A biochemical and physicochemical comparison of two recombinant enzymes used for enzyme replacement therapies of hunter syndrome. Glycoconj J. 2014;31(4):309–315. doi: https://doi.org/10.1007/s10719-014-9523-0

15. Sohn YB, Cho SY, Park SW, et al. Phase I/II clinical trial of enzyme replacement therapy with idursulfase beta in patients with mucopolysaccharidosis II (Hunter Syndrome). Orphanet J Rare Dis. 2013;8:67. doi: https://doi.org/10.1186/1750-1172-8-42

16. Sohn YB, Cho SY, Lee J, et al. Safety and efficacy of enzyme replacement therapy with idursulfase beta in children aged younger than 6 years with Hunter syndrome. Mol Genet Metab. 2015;114(2):156–160. doi: https://doi.org/10.1016/j.ymgme.2014.08.009

17. Muenzer J, Gucsavas-Calikoglu M, McCandless SE, et al. A phase I/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome). Mol Genet Metab. 2007;90(3):329–337. doi: https://doi.org/10.1016/j.ymgme.2006.09.001

18. Sawamoto K, Stapleton M, Alméciga-Díaz CJ, et al. Therapeutic Options for Mucopolysaccharidoses: Current and Emerging Treatments. Drugs. 2019;79(10):1103–1134. doi: https://doi.org/10.1007/s40265-019-01147-4

19. Bradley LA, Haddow HRM, Palomaki GE. Treatment of mucopolysaccharidosis type II (Hunter syndrome): Results from a systematic evidence review. Genet Med. 2017;19(11):1187–1201. doi: https://doi.org/10.1038/gim.2017.30

20. Dierenfeld AD, McEntee MF, Vogler CA, et al. Replacing the enzyme alpha-L-iduronidase at birth ameliorates symptoms in the brain and periphery of dogs with mucopolysaccharidosis type I. Sci Transl Med. 2010;2(60):60ra89. doi: https://doi.org/10.1126/scitranslmed.3001380

21. Vashakmadze ND, Namazova-Baranova LS, Zhurkova NV, et al. Mucopolysaccharidosis type II: Enzyme Replacement Therapy Efficiency. Voprosy sovremennoi pediatrii — Current Pediatrics. 2019;18(6):485–490. (In Russ). doi: https://doi.org/10.15690/vsp.v18i6.2070

22. Lagler FB. Current and Emerging Therapies for Mucopolysaccharidoses. Handb Exp Pharmacol. 2020;261:39–56. doi: https://doi.org/10.1007/164_2019_263

23. Xie H, Chung J-K, Mascelli MA, McCauley TG. Pharmacokinetics and bioavailability of a therapeutic enzyme (idursulfase) in cynomolgus monkeys after intrathecal and intravenous administration. PLoS ONE. 2015;10(4):e0122453. doi: https://doi.org/10.1371/journal.pone.0122453

24. Muenzer J, Beck M, Eng CM, et al. Long-term, open-labeled extension study of idursulfase in the treatment of Hunter syndrome. Genet Med. 2011;13(2):95–101. doi: https://doi.org/10.1097/GIM.0b013e3181fea459

25. Giugliani R, Harmatz P, Jones SA, et al. Evaluation of impact of anti-idursulfase antibodies during long-term idursulfase enzyme replacement therapy in mucopolysaccharidosis II patients. Mol Genet Metab Rep. 2017;12:2–7. doi: https://doi.org/10.1016/j.ymgmr.2017.01.014

26. Stephan BO, Quaio CR, Spolador GM, et al. Impact of ERT and follow-up of 17 patients from the same family with a mild form of MPS II. Clinics (Sao Paulo). 2022;77:100082. doi: https://doi.org/10.1016/j.clinsp.2022.100082